Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Šalek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A; 1804 (adept(TM)1) Investigators. de Paula EV, et al. Among authors: windyga j. J Thromb Haemost. 2012 Jan;10(1):81-9. doi: 10.1111/j.1538-7836.2011.04549.x. J Thromb Haemost. 2012. PMID: 22470921 Free article. Clinical Trial.
Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
Powell J, Martinowitz U, Windyga J, Di Minno G, Hellmann A, Pabinger I, Maas Enriquez M, Schwartz L, Ingerslev J; LipLong Study Investigators. Powell J, et al. Among authors: windyga j. Thromb Haemost. 2012 Nov;108(5):913-22. doi: 10.1160/TH12-03-0188. Epub 2012 Sep 26. Thromb Haemost. 2012. PMID: 23014711 Clinical Trial.
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.
Lentz SR, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN; adept™2 investigators. Lentz SR, et al. Among authors: windyga j. J Thromb Haemost. 2014 Aug;12(8):1244-53. doi: 10.1111/jth.12634. Epub 2014 Jul 16. J Thromb Haemost. 2014. PMID: 24931322 Free PMC article. Clinical Trial.
Inhibitor development in non-severe haemophilia across Europe.
Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M; EUHASS Participants. Fischer K, et al. Among authors: windyga j. Thromb Haemost. 2015 Oct;114(4):670-5. doi: 10.1160/TH14-12-1044. Epub 2015 Aug 13. Thromb Haemost. 2015. PMID: 26293381 Free article.
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.
Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K; adept™2 Investigators. Mahlangu JN, et al. Among authors: windyga j. J Thromb Haemost. 2015 Nov;13(11):1989-98. doi: 10.1111/jth.13141. Epub 2015 Oct 13. J Thromb Haemost. 2015. PMID: 26362483 Free article. Clinical Trial.
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Oldenburg J, et al. Among authors: windyga j. N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10. N Engl J Med. 2017. PMID: 28691557 Free article. Clinical Trial.
156 results